Progelatinase a mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival

Urology

Volumn 50, Issue 2, 1997, Pages 295-301

  Walther, McClellan M ^a,b   Kleiner, David E ^a   Lubensky, Irina A ^a   Pozzatti, Rudy ^a   Nyguen, Thai ^a   Gnarra, James R ^a   Hurley, Kathy ^a   Venzon, David ^a   Linehan, W Marston ^a   Stetler Stevenson, William G ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; GELATINASE A; MESSENGER RNA;

ARTICLE; CANCER SURVIVAL; CELL MOTION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; METASTASIS; NORTHERN BLOTTING; PRIORITY JOURNAL;

EID: 18244428624     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00220-3     Document Type: Article

References (34)

1. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
2. Nakajima M, Welch DR, Belloni PN, and Nicolson GL: Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 47: 4869-4876, 1987.
3. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, and Liotta LA: Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst 75: 99-103, 1985.
4. Otani N, Tsukamoto T, Saiki I, Yoneda J, Mitaka T, and Kumamoto Y: In vitro invasive potential and type IV collagenolytic activity of human renal cell carcinoma cells derived from primary and metastatic lesions. J Urol 149: 1182-1185, 1993.
5. Walther MM, Alexander RB, Weiss GI, Venzon D, Berman A, Pass HI, Linehan WM, and Rosenberg SA: Cytoreductive surgery prior to interleukin-2 based therapy in patients with metastatic renal cell carcinoma. Urology 42: 250-258, 1993.
6. Anglard P, Trahan E, Liu S, Latif F, Merino MJ, Lerman MI, Zbar B, and Linehan WM: Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res 52: 348-356, 1992.
7. Walther MM, Gnarra JR, Elwood L, Xu H-J, Florence C, Anglard P, Hu S-X, King C, Trahan E, Hurley K, et al: Loss of heterozygosity occurs centromeric to RB without associated abnormalities in the retinoblastoma gene in tumors from patients with metastatic renal cell carcinoma. J Urol 153: 2050-2054, 1995.
8. Reiter RE, Anglard P, Liu S, Gnarra JR, and Linehan WM: Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res 53: 3092-3097, 1993.
9. Brown PD, Levy AT, Margulies IM, Liotta LA, and Stetler-Stevenson WG: Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 50: 6184-6191, 1990.
10. Levy AT, Cioce V, Sobel ME, Garbisa S, Liotta LA, and Stetler-Stevenson WG: Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51: 439-444, 1991.
11. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, and Liotta LA: Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 265: 13933-13938, 1990.
12. Kleiner DE, and Stetler-Stevenson WG: Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218: 325-329, 1994.
13. Walther MM, Patel B, Choyke PL: Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. J Urol (in press).
14. Davies B, Brown PD, East N, Crimmin MJ, and Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087-2091, 1993.
15. Liotta LA, and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: 5054S-5059S, 1991.
16. Kishi J, Tanaka R, Koiwai O, Yamagata S, Numata Y, Hayakawa T, and Shimizu S: Gelatinases and metalloproteinase inhibitor secreted by murine colonic carcinoma cells with differing metastatic potential. Cell Biol Int 18: 165-170, 1994.
17. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, and Stetler-Stevenson WG: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83: 775-779, 1991.
18. Nuovo GJ, MacConnell PB, Simsir A, Valea F, and French DL: Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 55: 267-275, 1995.
19. Gohji K, Nakajima M, Fabra A, Bucana CD, von Eschenbach AC, Tsuruo T, and Fidler IJ: Regulation of gelatinase production in metastatic renal cell carcinoma by organ-specific fibroblasts. Jpn J Cancer Res 85: 152-160, 1994.
20. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, and Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem270: 5331-5338, 1995.
21. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, and Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61-65, 1994.
22. Turpeenniemi-Hujanen T, Thorgeirsson UP, Rao CN, and Liotta LA: Laminin increases the release of type IV collagenase from malignant cells. J Biol Chem 261: 1883-1889, 1986.
23. Azzam HS, Arand G, Lippman ME, and Thompson EW: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85: 1758-1764, 1993.
24. Urbanski SJ, Edwards DR, MaitlandA, Leco KJ, Watson A, and Kossakowska AE: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 66: 1188-1194, 1992.
25. Agarwal C, Hembree JR, Rorke EA, and Eckert RL: Transforming growth factor beta 1 regulation of metalloproteinase production in cultured human cervical epithelial cells. Cancer Res 54: 943-949, 1994.
26. Overall CM, Wrana JL, and Sodek J: Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J Biol Chem 264: 1860-1869, 1989.
27. Otani N, Tsukamoto T, Masumori N, Saiki I, Yoneda J, and Kumamoto Y: Influence of growth factors on in vitro invasiveness and type IV collagenolysis of human renal cell carcinoma cells. J Urol 151: 223-226, 1994.
28. Wade TP, Kasid A, Stein CA, LaRocca RV, Sargent ER, Gomella LG, Myers CE, and Linehan WM: Suramin interference with transforming growth factor-beta inhibition of human renal cell carcinoma in culture. J Surg Res 53: 195-198, 1992.
29. Gomella LG, Sargent ER, Linehan WM, and Kasid A: Transforming growth factor-beta inhibits the growth of renal cell carcinoma in vitro. J Urol 141: 1240-1244, 1989.
30. Kawamata H, Kameyama S, Nan L, Kawai K, and Oyasu R: Effect of epidermal growth factor and transforming growth factor beta 1 on growth and invasive potentials of newly established rat bladder carcinoma cell lines. Int J Cancer 55: 968-973, 1993.
31. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, and Stetler-Stevenson WG: Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 136: 585-592, 1990.
32. Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, and Giavazzi R: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58: 460-464, 1994.
33. Melchiori A, Albini A, Ray JM, and Stetler-Stevenson WG: Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res 52: 2353-2356, 1992.
34. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, and Miskin R: Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48: 3307-3312, 1988.